Neurogene Inc. 8-K

What Happened Neurogene Inc. filed a Form 8‑K on June 29, 2026 announcing "positive, updated clinical data" from its Phase 1/2 trial of NGN‑401 gene therapy in females with Rett syndrome. The company issued a press release and made a corporate presentation public, and scheduled a conference call and webcast for June 29, 2026 at 8:00 a.m. Eastern Time to discuss the results.

Key Details

• Press release announcing the data filed as Exhibit 99.1 (dated June 29, 2026).
• Corporate presentation on the updated data filed as Exhibit 99.2 (dated June 29, 2026).
• Conference call and webcast to discuss results: Monday, June 29, 2026 at 8:00 a.m. ET.
• The data relate to NGN‑401 in a Phase 1/2 trial specifically in females with Rett syndrome.

Why It Matters Positive, updated clinical data is a material development for Neurogene’s lead program and is likely to drive investor interest and news coverage. The filings provide the company’s official announcement and related materials for investors to review; the webcast offers management’s commentary on the results and next steps. There were no financial results or regulatory decisions reported in this Form 8‑K — investors should review the attached press release and presentation and listen to the call for full details.